RVMD
Revolution Medicines, Inc.$166.45-5.90 (-3.42%)Prev Close$172.29·MCap$39.08B·P/E—·Vol1.84M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
54
$161.32M
◆
Net Activity
Net Seller
$161.32M
●
Active Insiders
12
last 12 mo
Over the past 12 months, insider activity at Revolution Medicines, Inc. (RVMD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 54 insider sales totaling $161.32M. The most recent insider transaction was by Anders Jack (officer: Chief Financial Officer), who sold $6.72M worth of shares on Nov 13, 2026. Revolution Medicines, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $39.08B.
RVMD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 35,750 | $188.10 | $6.72M | 151,467 |
| Nov 12, 2026 | Mancini Anthony | officer: See Remarks | Sell | 811 | $200.00 | $162.2K | 39,765 |
| Oct 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 2,310 | $186.99 | $431.9K | 39,765 |
| Oct 1, 2026 | Sandler Alan B. | officer: Chief Development Officer | Sell | 6,309 | $202.14 | $1.28M | 56,668 |
| Sep 29, 2026 | Cislini Jeff | officer: SVP & General Counsel | Sell | 765 | $207.32 | $158.6K | 51,776 |
| Sep 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,708 | $200.45 | $743.3K | 39,765 |
| Sep 24, 2026 | ANDERSON ELIZABETH M | director | Sell | 10,143 | $193.04 | $1.96M | 13,566-43% |
| Sep 22, 2026 | Mancini Anthony | officer: See Remarks | Sell | 1,764 | $196.94 | $347.4K | 40,352 |
| Sep 18, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 4,967 | $199.24 | $989.6K | 154,571 |
| Sep 18, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 4,053 | $199.24 | $807.5K | 123,208 |
| Sep 18, 2026 | Cislini Jeff | officer: SVP & General Counsel | Sell | 3,366 | $199.24 | $670.6K | 55,855 |
| Sep 18, 2026 | Mancini Anthony | officer: See Remarks | Sell | 1,774 | $199.24 | $353.4K | 43,863 |
| Sep 18, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 13,988 | $199.24 | $2.79M | 267,117 |
| Sep 18, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 5,569 | $199.24 | $1.11M | 291,791 |
| Sep 18, 2026 | Sandler Alan B. | officer: Chief Development Officer | Sell | 341 | $199.24 | $67.9K | 53,204 |
| Sep 15, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 92,531 | $202.36 | $18.72M | 383,607 |
| Sep 14, 2026 | Mancini Anthony | officer: See Remarks | Sell | 15,448 | $204.16 | $3.15M | 53,319 |
| Sep 10, 2026 | Kim Lorence H. | director | Sell | 17,090 | $209.82 | $3.59M | 16,384-51% |
| Sep 2, 2026 | Kim Lorence H. | director | Sell | 56,000 | $203.24 | $11.38M | 72,790-43% |
| Aug 25, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 85,874 | $209.20 | $17.96M | 342,202 |
| Aug 25, 2026 | Cislini Jeff | officer: General Counsel | Sell | 56,894 | $209.24 | $11.90M | 109,401-34% |
| Jul 1, 2026 | Patel Sushil | director | Sell | 5,280 | $188.26 | $994.0K | 26,036 |
| Jun 26, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 20,000 | $168.33 | $3.37M | 138,716 |
| Jun 18, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 10,020 | $156.12 | $1.56M | 267,330 |
| Jun 18, 2026 | Mancini Anthony | officer: See Remarks | Sell | 4,615 | $156.12 | $720.5K | 49,975 |
| Jun 18, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,157 | $156.12 | $336.7K | 56,521 |
| Jun 18, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,722 | $156.12 | $425.0K | 123,269 |
| Jun 18, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,175 | $156.12 | $651.8K | 291,876 |
| Jun 17, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 93,575 | $160.00 | $14.97M | 158,222-37% |
| Jun 15, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 10,000 | $148.01 | $1.48M | 166,907 |
| May 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,121 | $153.99 | $480.6K | 56,821 |
| Apr 29, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,120 | $132.41 | $413.1K | 55,849 |
| Apr 17, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 120,000 | $150.09 | $18.01M | 276,698-30% |
| Mar 26, 2026 | Mancini Anthony | officer: See Remarks | Sell | 37,450 | $95.56 | $3.58M | 90,050-29% |
| Mar 19, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,753 | $99.48 | $273.9K | 125,512 |
| Mar 19, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,958 | $98.68 | $291.9K | 59,681 |
| Mar 19, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 12,871 | $99.48 | $1.28M | 276,698 |
| Mar 19, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 4,583 | $99.48 | $455.9K | 157,570 |
| Mar 19, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,302 | $99.48 | $428.0K | 295,398 |
| Mar 19, 2026 | Wang Xiaolin | officer: See Remarks | Sell | 2,010 | $99.48 | $200.0K | 116,063 |
| Mar 19, 2026 | Wei Lin | officer: Chief Medical Officer | Sell | 2,073 | $99.48 | $206.2K | 101,366 |
| Jan 21, 2026 | Cislini Jeff | General Counsel | Sell | 908 | $115.60 | $105.0K | 0 |
| Jan 9, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 73,300 | $100.51 | $7.37M | 162,957-31% |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $98.00 | $980.0K | 0 |
| Jan 7, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 75,000 | $100.56 | $7.54M | 0 |
| Dec 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 3,104 | $77.09 | $239.3K | 0 |
| Dec 16, 2025 | Cislini Jeff | General Counsel | Sell | 2,688 | $76.82 | $206.5K | 0 |
| Dec 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 15,394 | $76.82 | $1.18M | 0 |
| Dec 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 4,847 | $76.82 | $372.3K | 0 |
| Dec 16, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 5,447 | $76.82 | $418.4K | 0 |
Showing 1–50 of 219
1 / 5
RVMD Insider Buying Activity
The following table shows recent insider purchases of Revolution Medicines, Inc. (RVMD) stock reported via SEC Form 4 filings.
No insider buying activity found for RVMD in the last 12 months.
RVMD Insider Selling Activity
The following table shows recent insider sales of Revolution Medicines, Inc. (RVMD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 35,750 | $188.10 | $6.72M | 151,467 |
| Nov 12, 2026 | Mancini Anthony | officer: See Remarks | Sell | 811 | $200.00 | $162.2K | 39,765 |
| Oct 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 2,310 | $186.99 | $431.9K | 39,765 |
| Oct 1, 2026 | Sandler Alan B. | officer: Chief Development Officer | Sell | 6,309 | $202.14 | $1.28M | 56,668 |
| Sep 29, 2026 | Cislini Jeff | officer: SVP & General Counsel | Sell | 765 | $207.32 | $158.6K | 51,776 |
| Sep 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,708 | $200.45 | $743.3K | 39,765 |
| Sep 24, 2026 | ANDERSON ELIZABETH M | director | Sell | 10,143 | $193.04 | $1.96M | 13,566-43% |
| Sep 22, 2026 | Mancini Anthony | officer: See Remarks | Sell | 1,764 | $196.94 | $347.4K | 40,352 |
| Sep 18, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 4,967 | $199.24 | $989.6K | 154,571 |
| Sep 18, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 4,053 | $199.24 | $807.5K | 123,208 |
| Sep 18, 2026 | Cislini Jeff | officer: SVP & General Counsel | Sell | 3,366 | $199.24 | $670.6K | 55,855 |
| Sep 18, 2026 | Mancini Anthony | officer: See Remarks | Sell | 1,774 | $199.24 | $353.4K | 43,863 |
| Sep 18, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 13,988 | $199.24 | $2.79M | 267,117 |
| Sep 18, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 5,569 | $199.24 | $1.11M | 291,791 |
| Sep 18, 2026 | Sandler Alan B. | officer: Chief Development Officer | Sell | 341 | $199.24 | $67.9K | 53,204 |
| Sep 15, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 92,531 | $202.36 | $18.72M | 383,607 |
| Sep 14, 2026 | Mancini Anthony | officer: See Remarks | Sell | 15,448 | $204.16 | $3.15M | 53,319 |
| Sep 10, 2026 | Kim Lorence H. | director | Sell | 17,090 | $209.82 | $3.59M | 16,384-51% |
| Sep 2, 2026 | Kim Lorence H. | director | Sell | 56,000 | $203.24 | $11.38M | 72,790-43% |
| Aug 25, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 85,874 | $209.20 | $17.96M | 342,202 |
| Aug 25, 2026 | Cislini Jeff | officer: General Counsel | Sell | 56,894 | $209.24 | $11.90M | 109,401-34% |
| Jul 1, 2026 | Patel Sushil | director | Sell | 5,280 | $188.26 | $994.0K | 26,036 |
| Jun 26, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 20,000 | $168.33 | $3.37M | 138,716 |
| Jun 18, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 10,020 | $156.12 | $1.56M | 267,330 |
| Jun 18, 2026 | Mancini Anthony | officer: See Remarks | Sell | 4,615 | $156.12 | $720.5K | 49,975 |
| Jun 18, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,157 | $156.12 | $336.7K | 56,521 |
| Jun 18, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,722 | $156.12 | $425.0K | 123,269 |
| Jun 18, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,175 | $156.12 | $651.8K | 291,876 |
| Jun 17, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 93,575 | $160.00 | $14.97M | 158,222-37% |
| Jun 15, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 10,000 | $148.01 | $1.48M | 166,907 |
| May 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,121 | $153.99 | $480.6K | 56,821 |
| Apr 29, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,120 | $132.41 | $413.1K | 55,849 |
| Apr 17, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 120,000 | $150.09 | $18.01M | 276,698-30% |
| Mar 26, 2026 | Mancini Anthony | officer: See Remarks | Sell | 37,450 | $95.56 | $3.58M | 90,050-29% |
| Mar 19, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,753 | $99.48 | $273.9K | 125,512 |
| Mar 19, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,958 | $98.68 | $291.9K | 59,681 |
| Mar 19, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 12,871 | $99.48 | $1.28M | 276,698 |
| Mar 19, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 4,583 | $99.48 | $455.9K | 157,570 |
| Mar 19, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,302 | $99.48 | $428.0K | 295,398 |
| Mar 19, 2026 | Wang Xiaolin | officer: See Remarks | Sell | 2,010 | $99.48 | $200.0K | 116,063 |
| Mar 19, 2026 | Wei Lin | officer: Chief Medical Officer | Sell | 2,073 | $99.48 | $206.2K | 101,366 |
| Jan 21, 2026 | Cislini Jeff | General Counsel | Sell | 908 | $115.60 | $105.0K | 0 |
| Jan 9, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 73,300 | $100.51 | $7.37M | 162,957-31% |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $98.00 | $980.0K | 0 |
| Jan 7, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 75,000 | $100.56 | $7.54M | 0 |
| Dec 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 3,104 | $77.09 | $239.3K | 0 |
| Dec 16, 2025 | Cislini Jeff | General Counsel | Sell | 2,688 | $76.82 | $206.5K | 0 |
| Dec 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 15,394 | $76.82 | $1.18M | 0 |
| Dec 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 4,847 | $76.82 | $372.3K | 0 |
| Dec 16, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 5,447 | $76.82 | $418.4K | 0 |
RVMD Insiders
Similar Stocks to RVMD
VRTX
Vertex Pharmaceuticals Incorporated
$536.14-0.42%
$138.69B
REGN
Regeneron Pharmaceuticals, Inc.
$948.88-0.62%
$99.23B
MRNA
Moderna, Inc.
$214.97-3.55%
$93.61B
INSM
Insmed Incorporated
$122.96+1.38%
$26.58B
UTHR
United Therapeutics Corporation
$585.50-0.96%
$25.18B
INCY
Incyte Corporation
$120.12-0.66%
$24.66B
ALNY
Alnylam Pharmaceuticals, Inc.
$159.51-3.31%
$21.41B
NBIX
Neurocrine Biosciences, Inc.
$165.17-1.30%
$16.94B